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Abstract 
Nitroglycerin exerts a direct myocardial anti-ischemic effect even in the state 
of vascular nitrate tolerance. To examine the potentially diverse molecular responses 
in vascular and cardiac tissues, we investigated the gene expression profile of the 
heart and the aorta by DNA microarray in male Wistar rats that were previously 
made tolerant to the vascular effects of nitroglycerin. The blood pressure lowering 
effect of nitroglycerin (1–100 µg/kg) was markedly attenuated in rats pre-treated for 
3 days with 3x100 mg/kg nitroglycerin. Nitric oxide content was significantly elevated 
in the heart but not in the aorta of nitrate-tolerant animals, which indicated tissue-
specific differences in nitroglycerin bioconversion. Out of 7742 genes analyzed by 
DNA microarray, we found that while the expression of 25 genes changed 
significantly in the heart (increased: Tas2r119, Map6, Cd59, Kcnh2, Kcnh3, Senp6, 
Mcpt1, Tshb, Haus1, Vipr1, Lrn3, Lifr; decreased: Ihh, Fgfr1, Cryge, Krt9, Agrn, 
C4bpb, Fcer1a, Csf3, Hsd17b11, Hsd11b2, Ctnnbl1, Prpg1, Hsf1), only 14 genes 
were altered in the aorta (increased: Tas2r119, Ihh, Rrad, Npm1, Snai1; decreased: 
Tubb2b, Usp15, Sema6c, Wfdc2, Rps21, Ramp2, Galr1, Atxn1, Lhx1) in vascular 
nitrate tolerance. QRT-PCR analysis of genes related to oxidative/nitrative/nitrosative 
stress also showed differential expression pattern in the heart and aorta. This is the 
first pharmacogenomic analysis showing that nitroglycerin treatment leading to 
vascular nitrate tolerance differentially impacts gene expression in vascular and 
cardiac tissues, which indicates different tissue-specific downstream signaling 
pathways.  
Keywords: NOX; NOX4; matrix metalloproteinase; SOD; heat shock;  
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1. Introduction 
Organic nitrates have been among the most widely used drugs for the 
treatment of ischemic heart disease, a leading cause of death, for more than a 
century. The major effect of nitrates has been attributed to their vasodilator function 
and the resulting reduction of cardiac preload and afterload. However, development 
of vascular tolerance due to prolonged use reduces the clinical effectiveness of 
nitrate therapy. The principal causes of vascular nitrate tolerance are believed to be 
decreased bioavailability of nitric oxide (NO) derived from nitrates, counter-regulatory 
neurohormone activation and oxidative/nitrative/nitrosative stress1,2. Despite the 
potential for tolerance development, chronic nitrate use was associated with a shift 
away from ST-segment elevation myocardial infarction to non-ST-segment elevation 
acute coronary syndrome with smaller release of myocardial necrotic markers in a 
large scale clinical trial3. 
Interestingly, nitrates also exert a direct myocardial anti-ischemic effect, which 
is independent of their hemodynamic action and is preserved even in the state of 
vascular nitrate tolerance2,4,5. Moreover, Hill and coworkers6 have demonstrated in 
rabbit hearts that nitroglycerin treatment elicited a preconditioning-like effect 
comparable to ischemia-induced preconditioning, which was sustained even during 
development of nitrate tolerance. To explain the mechanisms of these phenomena, 
we have previously shown4,7 by spin trapping measurement of NO levels in nitrate-
tolerant and non-tolerant hearts that in contrast to vascular tissue, the bioconversion 
of nitroglycerin is not blunted in the myocardium. We have also found that oxidative 
stress was not increased in the heart during nitrate tolerance8. Based on these 
findings, it was proposed that the vasculature and cardiac tissue may respond to 
nitroglycerin treatment in a different way, questioning the existence of myocardial 
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nitrate tolerance2. To date, there is insufficient data regarding the potentially diverse 
cellular responses of vascular and cardiac tissues to organic nitrate treatments 
leading to the development of vascular nitrate tolerance, though the mechanism of 
nitrate action likely differ in these cell types2. Therefore, here we used DNA 
microarray analysis and QRT-PCR to monitor transcript levels in rat hearts and 
aortas with the hope of identifying critical differences in these tissues in response to 
nitroglycerin treatment which leads to vascular nitrate tolerance. 
 
2. Methods 
The study conforms to the ‘Guide for the care and use of laboratory animals’ 
published by the US National Institutes of Health (NIH publication No. 85–23, revised 
1996) and was approved by local ethics committees. The animals were kept at 12-
hour light/dark cycle and had free access to standard laboratory chow and drinking 
water. 
2.1. Nitrate treatment and verification of vascular nitrate tolerance 
To induce vascular nitrate tolerance (Figure 1.), male Wistar rats (300–360 g) 
were given nitroglycerin (100 mg/kg subcutaneously) or its vehicle (lactose) 3 times 
a day for 3 days as described in our earlier studies5,8,9. The animals were used for 
biochemical measurements on the fourth day (Figure 1.), approximately 12 h after 
the last injection, while the development of vascular tolerance to nitroglycerin was 
confirmed in a subgroup (n = 4 in each group) of animals in vivo (Figure 1.), 
according to the following protocol. The rats were anesthetized with an 
intraperitoneal injection of 60 mg/kg sodium pentobarbital, intubated via the trachea 
and then connected to a small animal respirator whose frequency and volume were 
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set at 50-55/min and 2.5 mL, respectively. The right carotid artery was isolated and a 
catheter (which was connected to a pressure transducer) was inserted for blood 
pressure (BP) monitoring. Similarly, the right jugular vein was isolated and 
catheterized for nitroglycerin administration. Body temperature was maintained at 
37 ± 1 °C throughout the experiment9. The test of vascular nitrate tolerance was 
conducted by recording the acute BP responses to intravenous administration of 
increasing doses of nitroglycerin (1 g/kg, 3 g/kg, 10 g/kg, 30 g/kg, and 
100 g/kg), in ten-minute intervals. The maximal BP-lowering effect was noted 
following administration of each nitroglycerin dose.  
2.2. Determination of cardiac and vascular NO content by electron 
paramagnetic resonance (EPR) 
To study potential tissue-specific differences in the metabolism of 
nitroglycerin, cardiac and aortic NO was measured by EPR after in vivo spin trapping 
from rats that were subjected to repeated nitroglycerin or vehicle injections. The spin 
trap diethyl-dithio-carbamate (DETC, 200 mg/kg), 50 mg/kg FeSO4 and 200 mg/kg 
sodium-citrate were slowly administered intravenously into the femoral vein under 
ether anesthesia as described earlier10. DETC dissolved in distilled water was 
injected separately from FeSO4 and sodium-citrate, to avoid precipitation of Fe
2+-
(DETC)2. Sodium-citrate and FeSO4 were dissolved in distilled water and pH was set 
to 7.4 with NaOH. Five minutes after DETC, FeSO4, and citrate treatment, the heart 
and the thoracic and abdominal aorta were isolated, rinsed in saline, and 
approximately 150 mg of the left ventricle and the entire aorta were placed into 
quartz EPR tubes and frozen in liquid nitrogen until assayed for EPR spectra of NO-
Fe2+-(DETC)2 complex, as described earlier
7,10.  
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EPR spectra of NO-Fe2+-(DETC)2 were recorded with a Bruker ECS106 
spectrometer (Rheinstetten, Germany; ESR parameters: X band, 100-kHz 
modulation frequency, 160-K temperature, 10-mW microwave power, 2.85-G 
modulation amplitude, 3356-G central field). Spectra were analyzed for NO signal 
intensity as described earlier7,10. Cardiac and aortic NO content were expressed as 
arbitrary units. 
2.3. Isolation of the heart and aorta for RNA preparation 
Animals were anesthetized with diethyl ether and given 500 U/kg heparin 
intravenously. Hearts from control and nitrate-treated rats (n = 8 in each groups) 
were then isolated and perfused in Langendorff mode with oxygenated, 
normothermic Krebs-Henseleit buffer for 5 min, as described in earlier works 4. 
Following isolation of the heart, the entire thoracic and abdominal aorta was 
dissected, placed in ice cold saline and trimmed of excess connective tissue. Then 
the ventricles and aortas from both experimental groups were blotted, immediately 
frozen, and powdered with a pestle and mortar in liquid nitrogen for RNA 
preparation. 
2.4. RNA preparation 
Total RNA was purified from each group (~25 mg tissue from each sample) 
with NucleoSpin RNA purification kit (Macherey-Nagel, Dürren, Germany) according 
to the manufacturer's instructions. The quantities and qualities of RNA from each 
sample were assessed by gel electrophoresis as well as spectrophotometry 
(NanoDrop spectrophotometer, NanoDrop, USA). Two RNA pools were prepared 
from each group (n = 4, randomly selected from each group) and used in replica 
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experiments. Total RNA was used for microarray analysis as well as for reverse 
transcription and subsequent quantitative PCR. 
2.5. Microarray analysis 
To monitor tissue-specific differences at the molecular level in cardiac and 
aortic tissues in response to nitroglycerin treatment that leads to vascular nitrate 
tolerance, we performed DNA microarray analysis. Microarray probes were 
generated by a modified version of a linear amplification technique described 
previously11. Briefly, two g of total RNA from each pooled sample was amplified. 
Three g of amplified RNA was labeled with both Cy5 and Cy3 fluorescent dyes 
(dye-swap experiments) during reverse transcription (RT) with RNAse H point 
mutant M-MLV reverse transcriptase (Fermentas, Vilnius, Lithuania) and random 
nonamers. After RT, RNA was alkali hydrolyzed and labeled cDNA was purified with 
NucleoSpinTM PCR purification kit (Macherey-Nagel) according to the manufacturer’s 
instructions. Probes generated from the control and treated samples were mixed, 
reconstituted in 16 L hybridization buffer (50% formamide, 5 x SSC, 0.1% SDS, 
100 g/mL salmon sperm DNA) and applied onto the array after denaturation by 
heating for 1 min at 90 ºC. Slides were incubated at 42 ºC for 20 hours in a humid 
hybridization chamber. After hybridization the arrays were washed by submersion 
and agitation for 10 min in 1 x SSC with 0.1% SDS, for 10 min in 0.1 x SSC with 
0.1% SDS and for 10 min in 0.1 x SSC at room temperature, then rinsed briefly in 
water and dried. 
Each array was scanned under a green laser (543 nm for Cy3 labeling) or a 
red laser (633 nm for Cy5 labeling) using a ScanArray Lite (GSI Lumonics, Billerica, 
MA) scanning confocal fluorescent scanner with 10 m resolution (Laser power: 85% 
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for Cy5 and 90% for Cy3, Gain: 75% for Cy5 and 70% for Cy3). Scanned output files 
were analyzed using the GenePix Pro 3.0 software (Axon Instruments Inc., Foster 
City, CA). Each spot was defined by automatic positioning of a grid of circles over 
the image. The average and median pixel intensity ratios calculated from both 
channels and the local background of each spot were determined. An average 
expression ratio (MeaR, denotes the average of local background corrected pixel 
intensity ratios) was determined for each spot. Normalization was performed by the 
global Lowess method. Those data were flagged and excluded where the replicate 
spots from a different site of the same array or results from the replicate experiments 
were significantly different. Data analysis was done by the Significance Analysis of 
Microarrays (SAM) method. Calculating the fold change in average between heart or 
aorta samples from non-tolerant and nitroglycerin-tolerant animals determined gene 
expression responses. From two biological replicates and two hybridizations, 
altogether four data points were gathered from each gene. Genes for which the 
average-log2 ratio (increase or decrease) of the four data points was at least 0.90 
and p < 0.05 were considered as genes affected by nitrate tolerance.  
2.6. Real-time quantitative PCR 
The confirmatory QRT-PCR was performed on a RotorGene 2000 instrument 
(Corbett Research, Sydney, Australia) with gene-specific primers and SybrGreen 
protocol to confirm the gene expression changes observed by DNA microarrays as 
described 12. Fluorescent signals were gathered after each extension step at 72 oC. 
Curves were analyzed by the RotorGene software using dynamic tube and slope 
correction methods, ignoring data from cycles close to baseline. Relative expression 
ratios were normalized to beta-actin and calculated with the Pfaffl method. The PCR 
primers used in this study are listed in Supplementary Material 1. A. Primers were 
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designed by using the ArrayExpress software (Applied Biosystems). All the PCRs 
were performed four times in separate runs. 
We also conducted additional QRT-PCR analyses of genes that are related to 
oxidative/nitrative/nitrosative stress and were not available on the microarray. The 
protocol for these analyses was identical to the above described method for the 
confirmatory QRT-PCR. The primers used in these analyses are listed in 
Supplementary Material 1. In separate experiments, additional QRT-PCR was 
conducted focusing on transcript levels of selected vascular signaling molecules 
(Supplementary Material 2.). 
2.7. Statistics 
Gene expression with p < 0.05 and log2 ratio ≥ 0.90 or log2 ratio ≤ -0.90 
(1.87 fold change) were considered as significant up- or down-regulation, 
respectively. One-way ANOVA or unpaired t-test, as appropriate, was used to 
calculate the differences in other parameters, such as the hemodynamic values or 
tissue nitric oxide content, between groups (p < 0.05). 
 
3. Results 
As expected, nitrate-tolerant animals exhibited a significantly attenuated acute 
blood pressure response during our nitroglycerin tolerance test (for explanation see 
the methods section) (Figure 2). However, there were no differences in body weight, 
heart weight, and basal ex vivo hemodynamic parameters between the nitrate-
tolerant and the non-tolerant rats (Table 1). 
To study potential tissue-specific differences in the metabolism of 
nitroglycerin, cardiac and aortic NO content were measured by EPR after in vivo spin 
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trapping from rats that were subjected to repeated nitroglycerin or vehicle injections. 
Nitric oxide content was significantly elevated in the heart but not in the aorta of 
nitrate-tolerant animals when compared to non-tolerant controls (Figure 3). 
To assess tissue-specific responses to repeated nitroglycerin pretreatments at 
the transcript level, expression of 7742 genes were analyzed by DNA microarray and 
the expression of 25 genes changed significantly in the heart, while 14 genes were 
altered in the aorta in vascular nitrate tolerance. 
The result of the analysis indicates that the expression of twelve genes 
increased (taste receptor type 2 member 119, microtubule-associated protein 6, 
CD59 molecule, potassium voltage-gated channel subfamily H member 2, potassium 
voltage-gated channel subfamily H member 3, SUMO1/sentrin specific peptidase 6, 
mast cell protease 1, thyroid stimulating hormone beta, HAUS augmin-like complex 
subunit 1, vasoactive intestinal peptide receptor 1, leucine rich repeat neuronal 3, 
leukemia inhibitory factor receptor alpha) and thirteen genes decreased (indian 
hedgehog, fibroblast growth factor receptor 1, crystallin gamma E, keratin 9, agrin, 
complement component 4 binding protein beta, Fc fragment of IgE, colony 
stimulating factor 3, hydroxysteroid (17-beta) dehydrogenase 11, hydroxysteroid 11-
beta dehydrogenase 2, catenin beta like 1, proline-rich proteoglycan 1, heat shock 
transcription factor 1) in the heart (Table 2 and Table 3), while five increased (taste 
receptor type 2 member 119, indian hedgehog, ras-related associated with diabetes, 
nucleophosmin, snail family zinc finger 1) and nine decreased (tubulin beta 2B 
class IIb, ubiquitin specific peptidase 15, semaphoring 6C, WAP four-disulfide core 
domain 2, ribosomal protein S21, receptor activity modifying protein 2, galanin 
receptor 1, ataxin 1, LIM homeobox 1) in the aorta (Table 2 and Table 4) satisfying 
both our threshold (at least ± 0.90 log2 ratio) and statistical significance (p < 0.05) 
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criteria. More importantly, there was an agreement regarding gene expression in 
case of only one gene (taste receptor type 2 member 119) in these tissues (Table 2). 
Apart from this gene, we found only one additional transcript (indian hedgehog) 
whose expression was altered by nitrate treatment in both tissues, but the direction 
of change was the opposite in the heart and the aorta; that is, gene expression 
decreased in the heart and increased in the aorta (Table 2). Selected significant 
cDNA microarray changes were verified with QRT-PCR in the case of ten genes in 
the heart and five genes in the aorta (Tables 2, 3, and 4).  
We also conducted additional QRT-PCR analysis of genes that were absent 
from the DNA microarray and may be important in relation to 
oxidative/nitrative/nitrosative stress. The outcome of this analysis confirmed the 
microarray results, indicating that the gene expression pattern was dissimilar in the 
heart and the aorta. Although the levels of two transcripts, nicotinamide adenine 
dinucleotide phosphate oxidase (NOX) 4 and nitric oxide synthase (NOS) 2 were 
elevated in both tissues, other changes were different (Table 5). For example, 
superoxide dismutase (SOD) 2 and SOD3 and matrix metalloproteinase (MMP) 2 
expression were increased in the aorta, but not in the heart. Additionally, transcript 
levels of tissue inhibitor of MMP1 decreased in the aorta, with no change in the 
heart, while tissue inhibitor of MMP4 decreased in the heart and remained 
unaffected in the aorta. 
The transcript levels of selected vascular signaling molecules were further 
investigated by QRT-PCR. There were no significant changes in expression of these 
selected genes (i.e. PDE1A, PDE2A2, AGTR1a, AGTR1b, GUCY1A2, GUCY1A3, 
GUCY1B2, GUCY1B3) in response to chronic nitroglycerin treatment 
(Supplementary Material 2.). 
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4. Discussion and conclusion 
In the present pharmacogenomic study, we demonstrated for the first time that 
the gene expression pattern in the heart and aorta remarkably differs in response to 
a nitroglycerin treatment that leads to the development of vascular nitrate tolerance. 
In our microarray analysis study, only one gene (taste receptor type 2 member 119) 
showed similar change in these tissues regarding the direction and magnitude of the 
alteration. Expression of only one other gene (indian hedgehog) was altered 
significantly but in an opposite direction in the heart and the aorta. All other genes 
showing significantly altered expression in the heart were unaffected in the aorta in 
response to a nitroglycerin treatment that leads to vascular nitrate tolerance. 
Furthermore, genes with altered expression in the aorta were not influenced in the 
heart. These data suggest that the repeated nitroglycerin treatment induces a tissue-
specific response at the transcript level. The tissue-specific differences were further 
confirmed in our present study by demonstrating that repeated nitroglycerin 
treatment resulted in an increased NO content in the heart but not in the aorta.  
The well-known cardioprotective effects of nitroglycerin, at least in part, are 
attributed to the drug’s vasodilator function and consequent reduction of cardiac 
preload and afterload. Development of vascular tolerance with prolonged use, 
however, reduces the hemodynamic effectiveness of nitrate therapy. Nevertheless, 
nitroglycerin exerts a direct myocardial anti-ischemic effect that remains preserved, 
even in the state of vascular nitrate tolerance induced by chronic nitrate 
treatment2,4,5,8, however, the underlying mechanisms of nitrate-induced 
cardioprotection are not entirely clear. To date, only two studies have investigated 
alterations of vascular gene expression in nitrate-tolerance13,14 along with one 
additional study having analyzed cardiac gene expression in response to a 4-day 
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treatment with organic nitrates15. However, these studies are substantially different in 
comparison to our work, because they have only focused on either the aorta or the 
heart. Moreover, Wang et al.14 have applied a very short 8-hour nitroglycerin 
infusion, thereby allowing observations only of early changes following nitroglycerin 
treatment. Our present study is the first in the literature to conduct a parallel gene 
expression analysis in the heart and aorta in response to repeated nitroglycerin 
treatments that lead to the development of vascular nitrate tolerance. As our present 
study has revealed substantial tissue-specific differences in cardiac and aortic gene 
expression, it is plausible to conclude that these tissue-dependent genetic responses 
may partially account for the persistence of the cardioprotective effect of nitroglycerin 
observed in the state of vascular nitrate tolerance2 and thereby may contribute to a 
better understanding and advancement of the field of long-term nitrate therapy.  
Results of our cDNA microarray analysis clearly showed that only two genes 
were altered significantly both in the heart and the aorta at the same time, in our 
present study. Expression of taste receptor type 2 member 119 was increased in 
both tissues, while the expression of indian hedgehog was decreased in the heart 
and increased in the aorta following nitroglycerin treatment. The G protein-coupled 
taste receptor type 2 is primarily found on the tongue playing a role in detection of a 
variety of nutrient compounds. It has been shown recently that the taste receptor 
type 2 is also expressed by the rodent and the human heart with a predicted nutrient 
sensor function16. Interestingly, taste receptor type 1 is suggested to inhibit 
autophagy by sensing extracellular amino acids in different tissues, including the 
heart17. In the vascular system taste receptor type 2 likely plays a role in regulation 
of vessel relaxation18. However, the precise role of cardiac and aortic taste receptors 
in the state of vascular nitrate tolerance remains to be elucidated. Indian hedgehog 
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participates in development and angiogenesis19, but its role in the state of vascular 
nitrate tolerance needs to be identified.  
Microarray analysis revealed several genes showing significantly altered 
expression only in the heart with no change in the aorta in response to nitroglycerin 
pretreatment that leads to vascular nitrate tolerance. Some of these genes have a 
clearly identified or suggested function in the heart. For instance, fibroblast growth 
factor receptor 1 plays a role in heart development20, postnatal cardiac remodeling21 
and mediation of protection against ischemic stimuli22; potassium voltage-gated 
channels contribute to maintaining the resting membrane potential and restoring it 
after depolarization23; heat shock factor 1 is responsible for regulation of heat shock 
proteins24; agrin modulates cardiomyocyte contraction25, and keratin may play a role 
in the rearrangement of desmoplakins into intercalated discs during the development 
of myocardium26. The exact role of these cardiac genes in the state of vascular 
nitrate tolerance induced by chronic nitroglycerin administration is not clear. In a 
large scale multi-center clinical study of 52,693 patients with acute coronary 
syndrome chronic nitrate therapy was associated with beneficial clinical presentation 
and smaller release of necrotic markers3, thus one may speculate that the increased 
expression of potassium voltage-gated channel subunits by chronic nitrate 
administration may improve the resistance of the heart against ischemia/reperfusion 
injury by shortening phase 3 repolarization and preventing cytosolic Ca2+ overload27. 
However, it has been also shown that nitroglycerin treatment leading to vascular 
nitrate tolerance interferes with the efficacy of myocardial pre-28 and 
postconditioning9. Along with others we have previously shown that inducible Hsp70 
(Hsp72) may play a role in ischemic tolerance29,30 and Hsp72 was implicated as a 
mediator of long-term cardioprotection31. Since in the present study heat shock 
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factor 1, a positive regulator of Hsp72 was decreased, one may speculate that 
dysregulation of HSF1/Hsp72 pathway in response to chronic nitrate treatment may 
interfere with cardioprotective mechanisms. The functional role of the other genes 
altered in our present study (e.g. Prpg1, Haus1, Vipr1) is not yet elucidated in 
cardiac physiology and their relations to treatment with NO-donors have not been 
shown.  
In our current study, we also showed several genes that were influenced 
exclusively in the aorta and were not altered in the heart in response to nitroglycerin 
treatment. Only a small percentage of these genes were shown to have a specific 
function in the vascular system. For example, tubulin plays a role in shear stress-
mediated regulation of vessel tone32; ras-related associated with diabetes GTP-
binding protein inhibits vascular lesion formation33; and receptor activity-modifying 
protein 2 contributes to adrenomedullin-induced vasorelaxation34. However, to the 
best of our knowledge, these genes were not yet described in connection with nitrate 
tolerance. Possible specific function of other genes altered in our present study (e.g. 
Usp15, Npm1, Wfdc2) has not yet been identified in the aorta.  
The metabolism of nitroglycerin was proposed to increase production of 
reactive oxygen intermediates (ROI)35. Moreover, ROIs are able to induce diverse 
cellular mechanisms that may possibly contribute to the development of vascular 
nitrate tolerance1 or direct nitroglycerin-induced cardioprotection36. Therefore, we 
performed additional QRT-PCR analysis of genes that are related to oxidative and 
nitrative/nitrosative stress. These tests also confirmed our initial hypothesis, 
indicating that the gene expression pattern was dissimilar in the heart and the aorta. 
Importantly, transcript levels of the predominant vascular NADPH oxidase isoform, 
NOX4, as well as SOD2 and SOD3 were increased in the aorta, likely reflecting an 
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augmented superoxide production in the state of nitrate tolerance. Moreover, MMP2 
was also elevated in the aorta, suggesting an increased oxidative stress, as ROI 
derived from either NOX activity or metabolism of nitroglycerin are likely involved in 
the expression of MMPs37. In our present study, the expression of NOX4 gene also 
increased in the heart in response to chronic nitrate treatment. However, the 
transcript level of SODs and MMPs were not altered and because the SOD enzymes 
are under transcriptional regulation by ROIs38, we conclude that nitroglycerin 
treatment did not result in oxidative stress in the myocardium, especially when 
compared to the aorta. This notion is in agreement with our previous results, 
indicating that vascular nitrate tolerance does not trigger oxidative stress in the 
heart8. In addition, the cardiac effects of NOX4 are controversial in the literature, 
both beneficial and deleterious effects have been indicated39,40. Furthermore, the 
predominant isoform in the adult heart is NOX237, whose expression remained 
unchanged in our study. These results, with their recognized limitations, tend to 
support the conclusion that free radical generation plays a role in the vascular effects 
of nitrate tolerance, however, in agreement with previous findings, vascular nitrate 
tolerance does not seem to result in increased oxidative and nitrative/nitrosative 
stress in the heart. 
In conclusion, this is the first pharmacogenomic analysis demonstrating that 
the heart and the aorta differentially respond to nitroglycerin treatment that causes 
vascular nitrate tolerance. Our findings may contribute to a better understanding of 
the Janus-faced nature of nitroglycerin, which is characterized by anti-anginal and 
direct cardioprotective effects, as well as development of tolerance and vascular 
dysfunction. We hope that our findings may help to open up novel directions in 
rational pharmacological design or development of drug combinations to prevent 
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tolerance development and facilitate cardioprotective effects of NO-donor molecules. 
Further research is needed to confirm our results in other models of nitrate tolerance, 
and to elucidate the exact role of differentially expressed genes in nitrate tolerance 
and nitrate-induced cardioprotection. 
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Figure legends 
Figure 1. Experimental protocol. Male Wistar rats were given subcutaneously 
nitroglycerin to induce vascular nitrate tolerance or its vehicle 3 times a day for 3 
days. On the fourth day hearts and aortas were isolated for DNA microarray analysis 
(n = 8 in each group), and the development of vascular tolerance to nitroglycerin was 
confirmed in a subgroup (n = 4 in each group) of animals in vivo.  
 
Figure 2. Validation of the development of vascular nitrate tolerance. Values 
represent mean arterial blood pressure following intravenous injection of increasing 
doses of nitroglycerin. Results are expressed as mean ± S.E.M. #p < 0.05 vs. 
baseline, *p < 0.05 vs. corresponding nitrate-tolerant group (n = 4 in each group). 
 
Figure 3. Cardiac and aortic NO content. The effect of systemic nitroglycerin 
pretreatment leading to vascular nitrate tolerance on cardiac and vascular nitric 
oxide (NO) content measured by electron paramagnetic resonance spectroscopy 
(EPR) after in vivo spin trapping. Results are expressed as mean ± S.E.M. *p < 0.05 
vs. non-tolerant group (n = 4 in each group). 
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Table 1. Morphological and ex vivo hemodynamic parameters. 
    Non-tolerant    Nitrate-tolerant 
Body Weight (g)  320±10    320±8 
Heart Weight (g)  1.2±0.1    1.3±0.1 
Heart Rate (bpm)  300±11    320±9 
Coronary Flow (mL/min) 15±1     15±2 
 
Results are expressed as mean ± S.E.M. 
Table 2. Results of DNA microarray analysis showing genes with significantly altered 
expression both in the heart and aorta in response to chronic nitroglycerin 
pretreatment. 
Values show gene expression in organs of nitrate-tolerant vs. non-tolerant rats. 
Log2 ratio reaching at least ± 0.90 and p < 0.05 were considered as significant 
alterations. Altered gene expressions were confirmed by QRT-PCR. 
a RGD: rat genome database 
   Heart Aorta 
Gene 
Function 
Gene Name 
provided by RGD
a
 
Accession 
Number 
Gene Symbol 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
signal 
transduction 
taste receptor, type 2, 
member 119 
AF227140 
Tas2r119 
1.83 
(0.78) 
3.56 
1.63 (0.43) 
YES 
1.75 
(0.07) 
3.38 
1.58 (0.04) 
YES 
development indian hedgehog 
AF162914 
Ihh 
-0.94 
(0.33) 
-1.92 
-1.22 (0.01) 
YES 
0.99 
(0.03) 
1.98 
1.26 (0.16) 
YES 
Table 3. Results of DNA microarray analysis showing genes with significantly altered 
expression only in the heart in response to chronic nitroglycerin pretreatment. 
Values show gene expression in organs of nitrate-tolerant vs. non-tolerant rats. 
Log2 ratio reaching at least ± 0.90 and p < 0.05 were considered as significant 
alterations. Altered expression of selected genes was confirmed by QRT-PCR. 
a RGD: rat genome database 
b n.d.: not detectable 
   Heart Aorta 
Gene 
Function 
Gene Name 
provided by RGD
a
 
Accession 
Number 
Gene Symbol 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
cell 
proliferation 
fibroblast growth factor 
receptor 1 
D12498 
Fgfr1 
-0.97 
(0.08) 
-1.96 
-1.21 (0.61) 
YES 
-0.65 
(-) 
-1.57 
0.35 (0.13) 
YES 
cell shape, 
structure 
microtubule-associated 
protein 6 
NM_017204 
Map6 
1.03 
(0.06) 
2.05 
1.02 (0.81) 
YES 
n.d.
b
 n.d. 
4.65 (0.68) 
- 
crystallin, gamma E 
J00716 
Cryge 
-1.03 
(0.50) 
-2.04 - 
0.10 
(0.34) 
1.07 - 
keratin 9 
NM_153476 
Krt9 
-0.97 
(0.36) 
-1.96 
-1.21 (0.19) 
YES 
-0.22 
(0.34) 
-1.16 
-0.9 (0.24) 
NO 
contraction 
regulation 
agrin 
M64780 
Agrn 
-1.35 
(0.14) 
-2.54 
-0.11 (0.7) 
NO 
n.d. n.d. 
0.49 (0.17) 
YES 
inflammatory 
response 
CD59 molecule, 
complement regulatory 
protein 
NM_012925 
Cd59 
0.97 
(0.09) 
1.96 
1.21 (0.26) 
YES 
-0.62 
(0.40) 
-1.54 
0.32 (0.05) 
YES 
complement component 
4 binding protein, beta 
NM_016995 
C4bpb 
-1.40 
(0.11) 
-2.64 
-0.18 (0.05) 
NO 
n.d. n.d. 
0.54 (0.72) 
- 
Fc fragment of IgE, high 
affinity I, receptor for 
alpha polypeptide 
NM_012724 
Fcer1a 
-1.72 
(0.17) 
-3.30 - n.d. n.d. - 
colony stimulating factor 3 
(granulocyte) 
NM_017104 
Csf3 
-1.77 
(0.01) 
-3.42 - 
-0.09 
(0.47) 
-1.06 - 
metabolism 
hydroxysteroid (17-beta) 
dehydrogenase 11 
BQ202947 
Hsd17b11 
-1.53 
(0.42) 
-2.88 - 
-0.71 
(0.39) 
-1.64 - 
hydroxysteroid 11-beta 
dehydrogenase 2 
NM_017081 
Hsd11b2 
-0.99 
(0.05) 
-1.99 
-1.14 (0.05) 
YES 
0.37 
(0.19) 
1.29 
2.01 (0.28) 
NO 
potassium 
transport 
potassium voltage-gated 
channel, subfamily H, 
member 2 
U75210 
Kcnh2 
0.90 
(0.06) 
1.87 
1.23 (0.48) 
YES 
-0.17 
(-) 
-1.13 
0.61 (0.09) 
YES 
potassium voltage-gated 
channel, subfamily H, 
member 3 
NM_017108 
Kcnh3 
3.30 
(0.75) 
9.85 
1.29 (0.22) 
YES 
-0.62 
(0.35) 
-1.53 
0.7 (0.78) 
YES 
proteolysis 
SUMO1/sentrin specific 
peptidase 6 
XM_217209 
Senp6 
0.99 
(0.04) 
1.98 - n.d. n.d. - 
mast cell protease 1 
U67915 
Mcpt1 
0.97 
(0.33) 
1.96 
0.27 (0.43) 
NO 
0.40 
(0.03) 
1.32 
-0.24 (0.53) 
YES 
signal 
transduction 
catenin, beta like 1 
NM_001024870 
Ctnnbl1 
-1.03 
(0.10) 
-2.04 - 
0.07 
(0.63) 
1.05 - 
proline-rich 
proteoglycan 1 
K02247 
Prpg1 
-1.89 
(0.21) 
-3.70 - n.d. n.d. - 
thyroid stimulating 
hormone, beta 
NM_013116 
Tshb 
1.10 
(0.43) 
2.15 
0.39 (0.33) 
NO 
n.d. n.d. 
0.44 (0.19) 
- 
HAUS augmin-like 
complex, subunit 1 
AF092207 
Haus1 
1.08 
(0.09) 
2.11 
-0.27 (0.11) 
NO 
n.d. n.d. 
-0.14 (0.31) 
- 
vasoactive intestinal 
peptide receptor 1 
NM_012685 
Vipr1 
0.97 
(0.01) 
1.96 
0.96 (0.41) 
YES 
-0.06  
(-) 
-1.04 
-0.38 (0.12) 
YES 
leucine rich repeat 
neuronal 3 
AF291437 
Lrrn3 
0.96 
(0.02) 
1.94 - 
0.29 
(0.24) 
1.22 - 
leukemia inhibitory factor 
receptor alpha 
D86345 
Lifr 
0.99 
(0.28) 
1.98 
0.32 (0.44) 
NO 
n.d. n.d. 
0.02 (0.31) 
- 
stress related 
heat shock 
transcription factor 1 
X83094 
Hsf1 
-1.29 
(0.06) 
-2.44 - n.d. n.d. - 
Table 4. Results of DNA microarray analysis showing genes with significantly altered 
expression only in the aorta in response to chronic nitroglycerin pretreatment. 
 
Values show gene expression in organs of nitrate-tolerant vs. non-tolerant rats. 
Log2 ratio reaching at least ± 0.90 and p < 0.05 were considered as significant 
alterations. Altered expression of selected genes was confirmed by QRT-PCR. 
a RGD: rat genome database 
b n.d.: not detectable 
   Aorta Heart 
Gene 
Function 
Gene Name 
provided by RGD
a
 
Accession 
Number 
Gene Symbol 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
Log2 
(SD) 
Fold 
Change 
QRT-PCR 
Log2 (SD) 
Confirmed 
cell shape, 
structure 
tubulin, beta 2B class IIb 
X03369 
Tubb2b 
-1.37 
(0.09) 
-2.58 
-1.02 (0.04) 
YES 
0.43 
(0.80) 
1.35 
0.01 (0.02) 
YES 
deubiquitination 
ubiquitin specific 
peptidase 15 
AF106657 
Usp15 
-2.98 
(0.10) 
-7.87 - 
-0.55 
(-) 
-1.46 - 
development 
semaphorin 6C (sema- 
TM- & cytoplasmic domain) 
AB000817 
Sema6c 
-0.94 
(0.01) 
-1.92 - 
0.68 
(0.23) 
1.60 - 
other 
WAP four-disulfide core 
domain 2 
NM_173109 
Wfdc2 
-1.67 
(0.02) 
-3.19 
-1.13 (0.19) 
YES 
n.d.
b
 n.d. 
0.78 (0.07) 
- 
protein 
synthesis 
ribosomal protein S21 
X79059 
Rps21 
-1.24 
(0.12) 
-2.37 - 
-0.27 
(0.66) 
-1.21 - 
signal 
transduction 
ras-related associated 
with diabetes 
U12187 
Rrad 
1.02 
(0.06) 
2.03 
1.22 (0.02) 
YES 
0.34 
(0.02) 
1.27 
0.08 (0.37) 
YES 
receptor activity 
modifying protein 2 
AB042888 
Ramp2 
-1.31 
(0.08) 
-2.48 
-0.23 (0.35) 
NO 
n.d. n.d. 
0.23 (0.08) 
- 
galanin receptor 1 
U30290 
Galr1 
-0.90 
(0.05) 
-1.87 - 
-0.20 
(-) 
-1.15 - 
transcription 
regulation 
nucleophosmin (nucleolar 
phosphoprotein B23) 
J04943 
Npm1 
0.96 
(0.08) 
1.94 - n.d. n.d. - 
snail family zinc finger 1 
AF295301 
Snai1 
1.16 
(0.10) 
2.23 - 
-0.65 
(1.69) 
-1.57 - 
ataxin 1 
NM_012726 
Atxn1 
-1.04 
(0.10) 
-2.05 - n.d. n.d. - 
LIM homeobox 1 
S71523 
Lhx1 
-0.91 
(0.02) 
-1.88 - n.d. n.d. - 
Table 5. QRT-PCR results of selected genes of oxidative/nitrative/nitrosative stress in 
the heart and the aorta in response to chronic nitroglycerin pretreatment. 
 
Values show gene expression in organs of nitrate-tolerant vs. non-tolerant rats. 
Log2 ratio at least ± 0.90 and p < 0.05 were considered as significant alterations 
(indicated with values in bold). 
  Heart Aorta 
Gene Name (Symbol) 
Accession 
Number 
Log2 (SD) 
Fold 
Change 
Log2 (SD) 
Fold 
Change 
matrix metalloproteinase 2 (MMP2) NM_031054 0.69 (0.26) 1.61 1.35 (0.1) 2.55 
matrix metalloproteinase 9 (MMP9) NM_031055 -0.08 (0.21 -1.06 0.30 (0.25) 1.23 
matrix metalloproteinase 13 (MMP13) AY135636 -0.16 (1.09) -1.12 -0.81 (0.87) -1.75 
NADPH oxidase 1 (NOX1) NM_053683 0.44 (0.23) 1.36 0.25 (0.45) 1.19 
NADPH oxidase 2 (CYBB) AJ295950.1 0.50 (0.61) 1.41 0.14 (0.3) 1.10 
NADPH oxidase 4 (NOX4) NM_053524 1.09 (0.03) 2.13 1.36 (0.13) 2.57 
nitric oxide synthase 1 (NOS1) NM_052799 -0.18 (0.2) -1.13 -0.73 (0.11) -1.66 
nitric oxide synthase 2 (NOS2) NM_012611 1.42 (0.21) 2.68 1.10 (0.07) 2.14 
nitric oxide synthase 3 (NOS3) NM_021838 0.12 (0.28) 1.09 0.23 (0.28) 1.17 
superoxide dismutase 1 (SOD1) NM_017050 0.34 (0.04) 1.27 0.48 (0.43) 1.39 
superoxide dismutase 2 (SOD2) X56600 -0.06 (0.28) 0.96 1.73 (0.08) 3.32 
superoxide dismutase 3 (SOD3) BC061861 0.48 (0.11) 1.39 1.15 (0.18) 2.22 
tissue inhibitor of MMP1 (TIMP1) NM_053819 -0.20 (0.61) -1.15 -1.31 (0.12) -2.48 
tissue inhibitor of MMP2 (TIMP2) NM_021989 -0.07 (0.82) -1.05 -0.04 (0.47) -1.03 
tissue inhibitor of MMP4 (TIMP4) NM_001109393 -1.40 (0.37) -2.64 -0.15 (0.13) -1.11 
Supplementary Material 1. 
Supplementary Table 1. Primers used for verifying DNA microarray results with QRT-PCR. 
 
a RGD: rat genome database 
  
Gene Name 
provided by RGD
a
 
Accession 
Number 
Forward primer Reverse primer 
actin, beta NM_031144 GGAAATCGTGCGTGACATTAAA TGCGGCAGTGGCCATC 
agrin M64780 TGGTTGTCCATGCTATTGACTTG GCCAGGCAAAATAGAAGCAGAT 
CD59 molecule, complement regulatory protein NM_012925 CAGGCCCTAGCAGGCATTT TCGACATCCAGGTGAAGCATAT 
complement component 4 binding protein, beta NM_016995 T GGAGCGCTTCCGTGACT TGTCCCAACTCTCTGTGTTACTTGA 
fibroblast growth factor receptor 1 D12498 CGGAAGCAACGCTGTGAAT TGGTAGATGGCAGCAATGGA 
HAUS augmin-like complex, subunit 1 AF092207 CCTGCAGTCTTCACCCGAAT TGGTCAGATCCTTGCCCTTT 
hydroxysteroid 11-beta dehydrogenase 2 NM_017081 GGAGAAGCGCAAGCAACTG TGCTCAATGTAGTCTTCACCATAGG 
indian hedgehog protein AF162914 CCGCGCGGTGGATATC CGCGCCAGTAGTCCGTACTT 
keratin 9 NM_153476 GCCTTCTGCTCAGCATCAAGA GCCGCCTTCAAGGAGCTT 
leukemia inhibitor factor receptor alpha D86345 TCCTGGCGAAAGCTCTGAGA TGATGGGTGGGCAGTAAGACA 
mast cell protease 1 U67915 TTTGCCAACTGCTCCTTGGT CATGGCCAGAAGCACATCCT 
microtubule-associated protein 6 NM_017204 CCAAAGACACAGGTACGGATCTG GCCCTTAGTTGGCTCAGGAA 
potassium voltage-gated channel, subfamily H, member 2 U75210 CCTTTTGCAGACCACCCTTGT GACACACGAGCCCCCATTAA 
potassium voltage-gated channel, subfamily H, member 3 NM_017108 CAGCCGGGAAACCGACTA AGTCGCACGGTTGGCATT 
ras-related associated with diabetes U12187 GCAGTACCGAGCCCTGACA GCAGCCATCATGTTCTTGGA 
receptor activity modifying protein 2 AB042888 GATTCGCTCAGTTCTGGAGACA GCGCCCCAGCAGCAT 
taste receptor, type 2, member 119 AF227140 AAACACAGACACACTGGACAAGCT TCTGCAGCACCTGTTCAGACA 
thyroid stimulating hormone, beta NM_013116 GCTCATTCTGCTGCTGGTCAT TCTTCAGTCTCCTTCAGCAGGAA 
tubulin, beta 2B class IIb X03369 TGTCCTTTGCCCTGGTGAA CTGGCCTAAGTGGACACATGAG 
vasoactive intestinal peptide receptor 1 NM_012685 CCTGACCATCAACACCACCAT GGAAGAAACAGTTTGCCATTGATA 
WAP four-disulfide core domain 2 NM_173109 CGGCTGCGGCTCTGTCT GCGGTCCTGGAGAGTTTTCC 
Supplementary Table 2. Primers used for QRT-PCR testing selected genes related to oxidative/nitrrative/nitrosative stress. 
 
Gene Name (Symbol) 
Accession 
Number 
Forward primer Reverse primer 
beta-actin NM_031144 CCCGCGAGTACAACCTTCT CGTCATCCATGGCGAACT 
matrix metalloproteinase 2 (MMP2) NM_031054 GCGCTTTTCTCGAATCCAT GGGTATCCATCTCCATGCTC 
matrix metalloproteinase 9 (MMP9) NM_031055 CCTCTGCATGAAGACGACATAA GGTCAGGTTTAGAGCCACGA 
matrix metalloproteinase 13 (MMP13) AY135636 GATGTGTGGCACAGTGGTTT GCCCAGGAAGCTTAGAACTCA 
NADPH oxidase 1 (NOX1) NM_053683 GGCATCCCTTTACTCTGACCT TGCTGCTCGAATATGAATGG 
NADPH oxidase 2 (CYBB) AJ295950.1 GCTGGGATTGGAGTCACG CCTGCACAGCCAGTAGAAGTAG 
NADPH oxidase 4 (NOX4) NM_053524 CCCTGTGCTGGCCACTAA TGGTGCCTCTCAGAGTCTACAAG 
nitric oxide synthase 1 (NOS1) NM_052799 GATGAGGCACCCCAACTCT CCTTTACGGGGAAAGAAACG 
nitric oxide synthase 2 (NOS2) NM_012611 ACCATGGAGCATCCCAAGTA CAGCGCATACCACTTCAGC 
nitric oxide synthase 3 (NOS3) NM_021838 TGACCCTCACCGATACAACA CGGGTGTCTAGATCCATGC 
superoxide dismutase 1 (SOD1) NM_017050 CCAGCGGATGAAGAGAGG GGACACATTGGCCACACC 
superoxide dismutase 2 (SOD2) X56600 TTCCTCTAATTGGGCTCAGG AGCTCTGGGGAAGACACGTA 
superoxide dismutase 3 (SOD3) BC061861 CTTGGGAGAGCTTGTCAGGT CACCAGTAGCAGGTTGCAGA 
tissue inhibitor of metalloproteinase 1 (TIMP1) NM_053819 CAGCAAAAGGCCTTCGTAAA TGGCTGAACAGGGAAACACT 
tissue inhibitor of metalloproteinase 2 (TIMP2) NM_021989 CTGGACGTTGGAGGAAAGAA ACAGAGGGTAATGTGCATCTTG 
tissue inhibitor of metalloproteinase 4 (TIMP4) NM_001109393 AGGGAGAGCCTGAATCATCA GCACTGCATAGCAAGTGGTG 
 
 
Supplementary Material 2. 
Methods 
In order to analyze the transcript levels of selected vascular signaling molecules 
by QRT-PCR separate experiments were performed. To induce vascular nitrate 
tolerance, male Wistar rats (320–400 g) were given nitroglycerin (100 mg/kg 
subcutaneously) or its vehicle (lactose) 3 times a day for 3 days. The animals were 
used for tissue sampling on the fourth day, approximately 12 h after the last injection. 
Animals were anesthetized with 50 mg/kg sodium pentobarbital and given 500 U/kg 
heparin intravenously. Hearts from non-tolerant and nitrate-tolerant rats (n = 6 in each 
groups) were then isolated and perfused in Langendorff mode with oxygenated, 
normothermic Krebs-Henseleit buffer for 5 min, as described in earlier works. Following 
isolation of the heart, the entire thoracic and abdominal aorta was dissected, placed in 
ice cold saline and trimmed of excess connective tissue. Then the ventricles and aortas 
from both experimental groups were blotted, immediately frozen, and powdered with a 
pestle and mortar in liquid nitrogen for RNA preparation. 
For QRT-PCR, 1 g samples of total RNA from individual samples were reverse 
transcribed using High Capacity Archive Kit (ABI, Foster City, California, USA). The 
reactions were carried out in final volume of 30 l. The RT reaction mixture was next 
diluted 2 times with sterile water. 1 l of the diluted reaction mix was used for QRT-PCR 
using SybrGreen dye. SybrGreen protocol were carried out with FastStart SYBR Green 
Master (Roche) in a RotorGene real-time QPCR machine (Corbett Research, Mortlake, 
Australia) according to manufacturer’s instructions at a final primer concentration of 250 
nM under the following conditions; 10 min at 95 oC, 45 cycles of 95 oC for 15 sec, 60 oC 
for 25 sec and 72 oC for 25 sec. The fluorescence intensity of SybrGreen dye was 
detected after each amplification step. Melting temperature analysis was done after 
each reaction to check the quality of the reaction. PCR primers were designed using the 
Universal Probe Library / Assay Design Center of Roche (http://lifescience.roche.com/ 
assay design center). A non-template control was used for each primer to check the 
primer dimer formation. All the Ct values were normalized to rat CyclophyllinA gene. 
 
Primers used for QRT-PCR testing selected genes of vascular signaling molecules. 
 
Gene Name (Symbol) 
Accession 
Number 
Forward primer Reverse primer 
phosphodiesterase 1A (PDE1A) NM_030871.1 
GCAACGCCTGAAAGGAA
TAC 
CGACAACGTTGACATC
ACCT 
phosphodiesterase 2A2 (PDE2A2) U21101 
CAACAAGCTTGGAGGAG
ACTTC 
GAGCACCGTGCCTGT
GTA 
angiotensin II receptor, type 1a 
(AGTR1a) 
NM_030985.4 
CACCCGATCACCGATCA
C 
CAGCCATTTTATACCA
ATCTCTCA 
angiotensin II receptor, type 1b 
(AGTR1b) 
NM_031009.2 
GACACACACAGCCTTTC
CAG 
GCTCTCTGACACTATT
TAAAATGCAC 
guanylate cyclase 1, soluble, beta 2 
(GUCY1B2) 
NM_012770.1 
GGAACACAGACCATCAG
CAA 
CCCAGCAAGTGTGACT
TCATT 
guanylate cyclase 1, soluble, beta 3 
(GUCY1B3) 
NM_012769.2 
GCCAATGCAAGTCTGGT
TTC 
CCATTCAGTTTTCATCC
TGGTT 
guanylate cyclase 1, soluble, alpha 
2 (GUCY1A2) 
NM_023956.1 
GCTGCAGTAGTGTCTCC
AAGC 
AGCTGAAGGACTCGGA
TGAA 
guanylate cyclase 1, soluble, alpha 
3 (GUCY1A3) 
NM_017090.2 
GCTTTGACCAACAGTGT
GGA 
AATATGCATCTCCGAT
GGTCTC 
 
  
Results 
QRT-PCR results of selected genes of vascular signaling molecules in the heart and the 
aorta in response to chronic nitroglycerin pretreatment. 
 
Values show gene expression in organs of nitrate-tolerant vs. non-tolerant rats. 
Log2 ratio at least ± 0.90 and p < 0.05 were considered as significant alterations. 
a not significant change (p > 0.05) 
b n.d.: not detectable 
 
 
  Heart Aorta 
Gene Name (Symbol) 
Accession 
Number 
Log2 (SD) 
Fold 
Change 
Log2 (SD) 
Fold 
Change 
phosphodiesterase 1A (PDE1A) NM_030871.1 n.d.
b
 n.d. n.d. n.d. 
phosphodiesterase 2A2 (PDE2A2) U21101 0.20 (0.55) 1.15 -0.28 (0.55) -1.22 
angiotensin II receptor, type 1a (AGTR1a) NM_030985.4 0.06 (0.37) 1.04 -1.02
a
 (1.64) -2.03 
angiotensin II receptor, type 1b (AGTR1b) NM_031009.2 0.19 (0.57) 1.14 -0.24 (1.09) -1.18 
guanylate cyclase 1, soluble, beta 2 (GUCY1B2) NM_012770.1 n.d. n.d. n.d. n.d. 
guanylate cyclase 1, soluble, beta 3 (GUCY1B3) NM_012769.2 0.44 (0.36) 1.36 -0.17 (0.73) -1.12 
guanylate cyclase 1, soluble, alpha 2 (GUCY1A2) NM_023956.1 -0.03 (0.79) -1.02 0.06 (0.80) 1.04 
guanylate cyclase 1, soluble, alpha 3 (GUCY1A3) NM_017090.2 n.d. n.d. n.d. n.d. 
